Durability of Response |
Total (N=76) |
Sirolimus (N=51) |
Vincristine
(N=25) |
*p-value |
Persistent disease 3 months from start of therapy, n (%) |
2/76 (2.6%) |
2/51 (3.9%) |
0/25 (0%) |
>0.9 |
Persistent disease 6 months from start of therapy, n (%) |
5/76 (6.6%) |
5/51 (9.8%) |
0/25 (0%) |
0.2 |
Time to persistent disease from start of systemic therapy (days), median
[IQR] |
566 [365.9-1493] |
414 [352-1148] |
1486
[1067-1902] |
0.2 |
Persistent disease requiring change in treatment agent, n (%) |
9/76
(11.8%) |
7/51 (13.7%) |
2/25 (8%) |
0.7 |
Persistent disease requiring continuation of current therapy, n (%) |
14/76 (18.4%) |
14/51 (27.5%) |
0/25 (0%) |
0.003 |
Recurrent disease 3 months from start of therapy, n (%) |
2/76 (2.6%) |
1/51 (2%) |
1/25 (4%) |
>0.9 |
Recurrent disease 6 months from start of therapy, n (%) |
1/76 (1.3%) |
0/51 (0%) |
1/25 (4%) |
0.3 |
Time to recurrent disease from start of systemic therapy (days), median
[IQR] |
825.5 [372.3-1273.5] |
1024 [583-1318] |
379
[231-913] |
0.3 |
Recurrent disease requiring change in treatment agent, n (%) |
8/76
(10.5%) |
5/51 (9.8%) |
3/25 (12%) |
>0.9 |
Recurrent disease requiring re-initiation of prior therapy, n (%) |
13/76 (17.1%) |
11/51 (21.6%) |
2/25 (8%) |
0.2 |
Progressive disease 3 months from start of therapy, n (%) |
1/76
(1.3%) |
1/51 (2%) |
0/25 (0%) |
>0.9 |
Progressive disease 6 months from start of therapy, n (%) |
1/76
(1.3%) |
1/51 (2%) |
0/25 (0%) |
>0.9 |
Time to progressive disease from start of systemic therapy (days),
median [IQR] |
730 [395-885] |
730 [562.5-1215] |
553
[387-719] |
0.8 |
Progressive disease requiring change in treatment agent, n (%) |
3/76
(3.9%) |
2/51 (3.9%) |
1/25 (4%) |
>0.9 |
Progressive disease requiring re-initiation of prior therapy, n (%) |
3/76 (3.9%) |
2/51 (3.9%) |
1/25 (4%) |
>0.9 |